NEWS COMMENTARY

Oxford Nanopore prepares for a $3 billion IPO

Published:
April 01, 2021
Last Updated:
April 01, 2021
Services:
Chemicals More...
Priorities:
Achieving Sustainability More...
Activities:
Markets More...
Very important

Oxford Nanopore's nanopore technology has come into the limelight since the COVID-19 outbreak. Since then, it has supported scientists in over 85 countries in tracking the emergence of new mutant variants. This field validation and its ability to overcome various technical hurdles sets the stage for the company to be the next major disruptor in genomics, challenging the dominance of Illumina. Clients keen on portable sequencing solutions for precision medicine, food safety and crop science use cases should consider integrating these solutions into their operations. Clients in the genomic sequencing value chain, from bioinformatics developers to chemical and material suppliers, must be prepared as nanopore sequencing becomes more mainstream.

For the original news article, click here .


Further Reading

Molzym

Company Profile | June 17, 2021

Molzym was founded by Michael Lorenz in 2003 and was acquired by Gradian Diagnostics in December 2019 The company's core technology is a culture‑free enrichment method for bacterial and fungal DNA, which it sells as a kit or different components of the kit as needed by the end user It also ... Not part of subscription

Helix's pivot from consumer genomics to population genomics highlights broader shifts in the human genomics landscape

Case Study | July 29, 2021

Helix Genomics came into the spotlight a few years ago when it pioneered a digital marketplace concept for genomics where it used a dynamic consent model to allow third‑party developers to turn genomics data into personalized insights for the consumer. It also offered whole‑exome sequencing (WES), ... Not part of subscription

DeepMind's AlphaFold will fundamentally change protein-based medicine

News Commentary | August 10, 2021

Many diseases are related to proteins, and understanding their structures often leads to breakthroughs in medicine. In fact, many Nobel Prizes are given to researchers for solving protein structures. Yet there is still not a fast way to determine protein structure – many researchers spend thousands ... To read more, click here.